Compare DSP & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | BDTX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 171.9M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | BDTX |
|---|---|---|
| Price | $10.99 | $1.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $17.81 | $9.67 |
| AVG Volume (30 Days) | 303.0K | ★ 2.3M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $20.27 | N/A |
| Revenue Next Year | $16.88 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.11 | $1.66 |
| 52 Week High | $15.18 | $4.94 |
| Indicator | DSP | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 30.23 |
| Support Level | $9.68 | N/A |
| Resistance Level | $11.23 | $2.30 |
| Average True Range (ATR) | 0.90 | 0.13 |
| MACD | -0.17 | -0.04 |
| Stochastic Oscillator | 8.51 | 2.17 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.